Download Ophthalmic Immunomodulators - Blue Cross and Blue Shield of

Ophthalmic Immunomodulators
Prior Authorization with Quantity
Limit Program Summary
This program applies to FlexRx Open, FlexRx Closed, GenRx Open, GenRx Closed,
Medicaid and Health Insurance Marketplace formularies.
This is a FlexRx standard and GenRx standard prior authorization program.
FDA APPROVED INDICATIONS AND DOSAGE1,4
Agent
Indication
Restasis®
(cyclosporine
ophthalmic
emulsion)
Xiidra™
(lifitegrast
ophthalmic
solution)
Indicated to increase tear production in
patients whose tear production is
presumed to be suppressed due to ocular
inflammation associated with
keratoconjunctivitis sicca. Increased tear
production was not seen in patients
currently taking topical anti-inflammatory
drugs or using punctal plugs.
Treatment of the signs and symptoms of
dry eye disease.
Dosage and
Administration
Instill one drop of
ophthalmic emulsion twice a
day in each eye
approximately 12 hours
apart
One drop twice daily in each
eye (approximately 12
hours apart).
CLINICAL RATIONALE
Dry eye syndrome is a group of disorders of the tear film that are due to reduced tear
production or excess tear evaporation, associated with ocular discomfort and/or visual
symptoms and possible disease of the ocular surface. While the symptoms of dry eye
syndrome often improve with treatment, the disease usually is not curable.2
The ocular surface and tear-secreting glands function as an integrated unit. Disease or
dysfunction of this functional unit results in an unstable and poorly maintained tear film
that causes ocular irritation symptoms and possible damage to the ocular surface
epithelium. Dysfunction of this integrated unit may develop from aging, a decrease in
supportive factors (such as androgen hormones), systemic inflammatory disease (such
as Sjögren’s Syndrome or rheumatoid arthritis), ocular surface diseases or surgeries that
disrupt the trigeminal afferent sensory nerves, and systemic diseases or medication that
disrupt the efferent cholinergic nerves that stimulate tear secretion. Decreased tear
secretion and clearance initiates an inflammatory response on the ocular surface that
involves both soluble and cellular mediators. Clinical and basic research suggests that
this inflammation plays a role in the pathogenesis of dry eye.2
When there is an associated systemic disease such as Sjögren’s Syndrome, an
inflammatory cellular infiltration of the exocrine glands (including lacrimal gland) leads to
saliva and tear production deficiency. About 10% of patients with clinically significant
aqueous deficient dry eye have an underlying primary Sjögren’s Syndrome.2
The Sjogren’s Syndrome Foundation Guideline Management of Dry Eye Associated with
Sjögren Disease (U.S., 2015) states the following.3
 In general, therapy is based upon severity of disease and patient response to
each added therapy. The first line of therapy for dry eye in Sjögren disease has
MN_PS_Ophthalmic_Immunomodulators_PAQL_ProgSum_AR1016_r0117
© Copyright 01/2017 All Rights Reserved
Page 1 of 7

been volume replacement and lubrication with “artificial tears”, mostly available
OTC. Among the wide variety of tear supplements, none is clearly superior. 3
A management algorithm based upon level of severity of dry eye disease shows
progression of therapy is determined by response to prior treatment option. Early
disease begins with tear replacement; topically applied artificial tear or lubricant
solutions may be sufficient. Progressive or more severe keratoconjunctivitis sicca
(KCS) requires use of dietary supplements (omega 3 essential fatty acids), antiinflammatory measures (e.g., topical corticosteroids or cyclosporine), or oral
secretagogues.3
The American Academy of Ophthalmology has categorized dry eye into three severity
levels based on symptoms and signs. Because of the nature of the disease, the
classifications are imprecise as the characteristics overlap between levels of severity. 2
 Mild dry eye
o Symptoms of irritation, itching, soreness, ocular discomfort, burning or
intermittent blurred vision.
 Moderate dry eye
o Increased discomfort and frequency of symptoms, and negative effect on
visual function may become more consistent.
 Severe dry eye
o Increasing frequency of symptoms that may become constant as well as
potentially disabling visual symptoms.
The American Academy of Ophthalmology recommend treating mild dry eyes with the
following:2
 Education and environmental modifications
 Elimination of offending topical or systemic medications
 Aqueous enhancement using artificial tear substitutes, gels, or ointment
 Eyelid therapy (warm compresses and eyelid scrubs)
 Treatment of contributing ocular factors such as blepharitis or meibomiantitis
 Correction of eyelid abnormality
For treatment of moderate dry eye the following are recommended in addition to mild dry
eye treatment options:2
 Topical anti-inflammatory agents (topical cyclosporine and corticosteroids),
systemic omega 3 fatty acids supplements
 Punctal plugs
 Spectacle side shields and moisture chambers
For treatment of severe dry eye the following are recommended in addition to mild and
moderate dry eye treatment options:2
 Systemic cholinergic agonists
 Systemic anti-inflammatory agents
 Mucolytic agents
 Autologous serum tears
 Contact lenses
 Permanent punctal occlusion
 Tarsorrhaphy
Because of the inconsistent correlation between reported symptoms and clinical signs as
well as the relatively poor specificity and/or sensitivity of clinical tests, patients with
suggestive symptoms without signs should be placed on trial treatments with artificial
tears when other potential causes of ocular irritation have been eliminated. As the
severity of the dry eyes increases, aqueous enhancement of the eye using topical agents
MN_PS_Ophthalmic_Immunomodulators_PAQL_ProgSum_AR1016_r0117
© Copyright 01/2017 All Rights Reserved
Page 2 of 7
is appropriate. Emulsions, gels, and ointments can be used. The use of artificial tears
may be increased, but the practicality of frequent tear instillation depends on the lifestyle
or manual dexterity of the patient. Non-preserved tear substitutes are generally
preferable; however, tears with preservatives may be sufficient for patients with mild dry
eye and an otherwise healthy ocular surface. When tear substitutes are used frequently
and chronically (e.g. more than 4 times a day), non-preserved tears are generally
recommended. It is imperative to treat any causative factors that are amenable to
treatment. Tear replacement is frequently unsuccessful when used as the sole treatment
if additional causative factors are not concomitantly addressed.2
Anti-inflammatory therapies may be considered in addition to aqueous enhancement
therapies. However, since dry eye symptoms tend to wax and wane over long periods of
time, the lack of long-term data on the effectiveness of cyclosporine and the costs of
longer-term (e.g. annual, lifetime) treatment should be weighed. It is also unclear
whether the effects observed in cyclosporine ophthalmic emulsion clinical trials are
clinically significant, and many subgroups of dry eye patients (e.g. those with meibomian
gland dysfunction or keratoconjunctivitis sicca) are unlikely to experience the same
benefit.2
Efficacy
The efficacy of cyclosporine ophthalmic emulsion was studied in four multicenter,
randomized, adequate and well-controlled clinical studies in approximately 1,200 patients
with moderate to severe keratoconjunctivitis sicca. Cyclosporine ophthalmic emulsion
demonstrated statistically significant increases in Schirmer wetting of 10 mm versus
vehicle at six months in patients whose tear production was presumed to be suppressed
due to ocular inflammation. This effect was seen in approximately 15% of cyclosporine
ophthalmic emulsion-treated patients versus approximately 5% of vehicle-treated
patients. Increased tear production was not seen in patients currently taking topical antiinflammatory drugs or using punctal plugs.1
The efficacy of lifitegrast for the treatment of dry eye disease were assessed in a total of
1181 patients (1067 of which received lifitegrast 5%) in four 12-week, randomized,
multi-center, double-masked, vehicle-controlled studies. Eye dryness Score (EDS) was
rated by patients using a visual analogue scale (VAS) (0 = no discomfort, 100 = maximal
discomfort) at each study visit. In three of the four studies, lifitegrast showed statistically
significant improvement in EDS at day 84 vs. the vehicle [study 2 difference (95% CI): 4.7 (-8.9, -0.4), study 3 difference (95% CI): -12.3 (-16.4, -8.3), study 4 difference
(95% CI): -7.5 (-11.6, -3.5)]. Inferior fluorescein corneal staining score (ICSS) (0 = no
staining, 1 = few/rare punctate lesions, 2 = discrete and countable lesions, 3 = lesions
too numerous to count but not coalescent, 4 = coalescent) was recorded at each study
visit. At day 84, lifitegrast showed statistically significant improvement vs. vehicle in
three of the four studies [study 1 difference (95% CI): -0.25 (-0.50, -0.00), study 2
difference (95% CI): -0.23 (-0.36, -0.10), study 4 difference (95% CI): -0.17 (-0.30, 0.03)].4
Safety
Cyclosporine ophthalmic emulsion is contraindicated in those with hypersensitivity to the
product.1
Lifitegrast ophthalmic emulsion has no contraindications.4
For additional clinical information see the Prime Therapeutics Formulary Chapters 14.1B.
MN_PS_Ophthalmic_Immunomodulators_PAQL_ProgSum_AR1016_r0117
© Copyright 01/2017 All Rights Reserved
Page 3 of 7
REFERENCES
1. Restasis Prescribing Information. Allergan, Inc. June 2013.
2. Dry eye syndrome. American Academy of Ophthalmology. September 2013.
3. Foulks G, Forstot L, Donshik P, et al. Clinical guidelines for management of dry eye
associated with Sjögren disease. The Ocular Surface. 2015;13(2):118-132.
4. Xiidra prescribing information. Shire US, Inc. July 2016
MN_PS_Ophthalmic_Immunomodulators_PAQL_ProgSum_AR1016_r0117
© Copyright 01/2017 All Rights Reserved
Page 4 of 7
Ophthalmic Immunomodulators Prior Authorization with Quantity
Limit
OBJECTIVE
The intent of the Ophthalmic Immunomodulators prior authorization (PA) program is to
ensure appropriate selection of patients for treatment according to product labeling
and/or clinical studies and/or guidelines. The PA defines appropriate use for Restasis as
treatment for patients who have tear production presumed to be suppressed due to
ocular inflammation associated with keratoconjunctivitis sicca (e.g. Sjögren’s Syndrome).
The program will not approve for Restasis if the patient is also using a topical ophthalmic
anti-inflammatory drug or punctal plug. The program defines appropriate use for Xiidra
as treatment for patients with a diagnosis of dry eye disease. The program requires
patients to have previously tried or are currently using aqueous enhancements. The
program will also approve members who have another FDA labeled indication for the
requested agent. The program will not approve those with contraindication(s) to the
requested agent. Doses above the set limit will be approved if the requested quantity is
below the FDA limit or when the quantity is above the FDA limit and the prescriber has
submitted documentation in support of therapy with a higher dose for the intended
diagnosis. Requests will be reviewed when patient-specific documentation has been
provided.
TARGET DRUG
Restasis® (cyclosporine ophthalmic emulsion)
Xiidra™ (lifitegrast ophthalmic solution)
Brand (generic)
GPI/NDC
Restasis
(cyclosporine ophthalmic
emulsion) multidose bottle
GPI:
86720020001620
NDC:
00023-5301-05
86720020001620
Restasis
(cyclosporine ophthalmic
emulsion)
Xiidra
(lifitegrast ophthalmic
solution)
86734050002020
Multisource
Code
NA
Quantity Limit
M, N, O, or Y
2 vials / day
M, N, O, or Y
2 containers /
day
1 bottle / 30 days
PRIOR AUTHORIZATION CRITERIA FOR APPROVAL
Restasis (cyclosporine ophthalmic emulsion) will be approved when ALL of the
following are met:
1.
ONE of the following:
a. ALL of the following:
i. The patient has a diagnosis of tear production presumed to be
suppressed due to ocular inflammation associated with
keratoconjunctivitis sicca (e.g. Sjögren’s Syndrome)
AND
ii. ONE of the following:
1. The patient is not currently using a topical ophthalmic antiinflammatory drug or punctal plug
OR
MN_PS_Ophthalmic_Immunomodulators_PAQL_ProgSum_AR1016_r0117
© Copyright 01/2017 All Rights Reserved
Page 5 of 7
2. The patient’s current use of topical ophthalmic antiinflammatory drug or punctal plug will be discontinued
before starting the requested agent
AND
iii. ONE of the following:
1. The patient has previously tried or is currently using aqueous
enhancements (e.g. artificial tears, gels, ointments)
OR
2. The patient has a documented intolerance, FDA labeled
contraindication(s), or hypersensitivity to aqueous
enhancements (e.g. artificial tears, gels, ointments)
b.
2.
3.
OR
Other FDA approved indication
AND
The patient does not have any FDA labeled contraindication(s) to the requested
agent
AND
ONE of the following:
a. The requested quantity (dose) is NOT greater than the program quantity
limit
OR
b. ALL of the following:
i. The requested quantity (dose) is greater than the program quantity
limit
AND
ii. The prescriber has submitted documentation in support of therapy
with a higher dose for the intended diagnosis (must be reviewed by
the Clinical Review pharmacist)
Length of Approval: 12 months
Xiidra (lifitegrast ophthalmic solution) will be approved when ALL of the following
are met:
1.
ONE of the following:
a. ALL of the following:
i. The patient has a diagnosis of dry eye disease
AND
ii. ONE of the following:
1. The patient has previously tried or is currently using aqueous
enhancements (e.g. artificial tears, gels, ointments)
OR
2. The patient has a documented intolerance, FDA labeled
contraindication(s), or hypersensitivity to aqueous
enhancements (e.g. artificial tears, gels, ointments)
OR
b. Other FDA approved indication
AND
2.
The patient does not have any FDA labeled contraindication(s) to the requested
agent
AND
3.
ONE of the following:
MN_PS_Ophthalmic_Immunomodulators_PAQL_ProgSum_AR1016_r0117
© Copyright 01/2017 All Rights Reserved
Page 6 of 7
a. The requested quantity (dose) is NOT greater than the program quantity
limit
OR
b. ALL of the following:
i. The requested quantity (dose) is greater than the program quantity
limit
AND
ii. The prescriber has submitted documentation in support of therapy
with a higher dose for the intended diagnosis (must be reviewed by
the Clinical Review pharmacist)
Length of Approval: 12 months
MN_PS_Ophthalmic_Immunomodulators_PAQL_ProgSum_AR1016_r0117
© Copyright 01/2017 All Rights Reserved
Page 7 of 7